GRI Bio, Inc.
GRI
Rank in Stocks
#31108
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The companyโs portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Share Price
$1.71
Last synced: 2026-11-09
Market Cap
$3.74M
Change (1 day)
-9.04%
Change (1 year)
-96.70%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade GRI Bio, Inc. (GRI)
Category
Healthcare
Operating Margin for GRI Bio, Inc. (GRI)
Operating Margin as of November 2026 TTM: 0.00%
According to GRI Bio, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for GRI Bio, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -36.54% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -1,459.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about GRI Bio, Inc.'s operating margin
What was GRI Bio, Inc.'s operating margin in 2025?
In 2025, GRI Bio, Inc.'s operating margin was 0.00%, compared with -36.54% in 2024.
How has GRI Bio, Inc.'s operating margin changed since 2020?
From 2020 to 2025, GRI Bio, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-1,459.00%).
How does GRI Bio, Inc.'s operating margin compare with similar companies?
GRI Bio, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.